In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold rating on BioMarin Pharmaceutical, with a price target of $68.00.Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence
Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matteis covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, KalVista Pharmaceuticals, and Xenon. According to TipRanks, Matteis has an average return of 14.9% and a 51.20% success rate on recommended stocks.
In addition to Stifel Nicolaus, BioMarin Pharmaceutical also received a Hold from H.C. Wainwright’s Mitchell Kapoor in a report issued on May 22. However, on the same day, Raymond James maintained a Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN).
Based on BioMarin Pharmaceutical’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $766.21 million and a net profit of $105.53 million. In comparison, last year the company earned a revenue of $745.15 million and had a net profit of $185.69 million
